- AustraliaNorth AmericaWorld
Investing News NetworkYour trusted source for investing success
- Lithium Outlook
- Oil and Gas Outlook
- Gold Outlook Report
- Uranium Outlook
- Rare Earths Outlook
- All Outlook Reports
- Top Generative AI Stocks
- Top EV Stocks
- Biggest AI Companies
- Biggest Blockchain Stocks
- Biggest Cryptocurrency-mining Stocks
- Biggest Cybersecurity Companies
- Biggest Robotics Companies
- Biggest Social Media Companies
- Biggest Technology ETFs
- Artificial Intellgience ETFs
- Robotics ETFs
- Canadian Cryptocurrency ETFs
- Artificial Intelligence Outlook
- EV Outlook
- Cleantech Outlook
- Crypto Outlook
- Tech Outlook
- All Market Outlook Reports
- Cannabis Weekly Round-Up
- Top Alzheimer's Treatment Stocks
- Top Biotech Stocks
- Top Plant-based Food Stocks
- Biggest Cannabis Stocks
- Biggest Pharma Stocks
- Longevity Stocks to Watch
- Psychedelics Stocks to Watch
- Top Cobalt Stocks
- Small Biotech ETFs to Watch
- Top Life Science ETFs
- Biggest Pharmaceutical ETFs
- Life Science Outlook
- Biotech Outlook
- Cannabis Outlook
- Pharma Outlook
- Psychedelics Outlook
- All Market Outlook Reports
Asterion: Targeting Australia’s Pharmaceutical-Grade Cannabis Market
Asterion Cannabis Inc., a vertically-integrated cannabis company operating in Australia, has launched its campaign on INN’s Cannabis channel.
Asterion Cannabis Inc. has launched its campaign on the Investing News Network’s Cannabis channel.
Asterion is a vertically-integrated Canadian cannabis company focused on its operations in Australia. With the goal of being a leader in precision agriculture, the company is working on producing high-quality, low-cost and genetically-uniform cannabis strains and products. To achieve this goal, Asterion is developing a 4.3 million-square-foot pharmaceutical-grade medical cannabis facility in Southeast Queensland, Australia. Once fully developed, the facility will produce over 500,000 kilograms of cannabis annually.
Further establishing a footprint in Australia, the company has aligned itself with PreveCeutical Medical Inc. (CSE:PREV,OTCQB:PRVCF,FWB:18H), a preventive health sciences company focused on developing preventive medicine, to develop new cannabis-based preventive and curative therapies.
Asterion’s company highlights include the following:
- Developing a state-of-the-art 4.3-million-square-foot facility in Southeast Queensland, Australia.
- Southeast Queensland receives over 2,400 hours of sunlight annually.
- Will plant first cannabis crop after Phase 1 of construction is complete.
- Projected annual production of over 500,000 kilograms of cannabis once operational.
- Future product lines may include tinctures, oils, edibles, flower and gelatin capsules.
- Awaiting approval for cultivation and sales licenses.
- Strategic partnerships in place with PreveCeutical and White Sheep Corp.
- Management has over 120 years of combined experience in medical cannabis, renewable energy, capital markets, among other sectors across the globe.
Outlook Reports
Featured Cannabis Investing News Stocks
Browse Companies
MARKETS
COMMODITIES
Commodities | |||
---|---|---|---|
Gold | 2191.86 | +18.99 | |
Silver | 24.77 | +0.11 | |
Copper | 4.01 | 0.00 | |
Oil | 82.15 | +0.20 | |
Heating Oil | 2.65 | -0.01 | |
Natural Gas | 1.63 | +0.02 |
Investing News Network websites or approved third-party tools use cookies. Please refer to the cookie policy for collected data, privacy and GDPR compliance. By continuing to browse the site, you agree to our use of cookies.